CM
GRTX

Crestline Management’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Crestline Management’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-34,305
Closed -$45K – 280
2022
Q2 		$45K Sell
34,305
-444
-1% -$760 0.01% 218
2022
Q1 		$83K Buy
+34,749
New +$90.5K 0.01% 252

Other funds holding GRTX

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Crestline Management's GRTX Position: Q3 2022 in Review

Crestline Management sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q3 2022, closing a stake of 34,305 shares — an estimated $45K sold.

Crestline Management first reported a position in GRTX in Q1 2022 and held it in 2 quarters. The position peaked at $83K in Q1 2022. 33 funds tracked by Wall St. Rank hold GRTX as of Q3 2022.

  • Crestline Management reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Crestline Management sold 34,305 Galera Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $45K.
  • Crestline Management first reported a position in Galera Therapeutics, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Crestline Management's Galera Therapeutics, Inc. Common Stock position peaked at $83K in Q1 2022.
  • 33 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Crestline Management's 13F filing for Q3 2022, filed 14 Nov 2022.